Pregnancy With Glanzmann Thrombasthenia: What Women With GT Should Know

Can women with Glanzmann Thrombasthenia have a successful pregnancy? Yes. Pregnancy is possible for women with Glanzmann Thrombasthenia (GT), but it is considered high risk and requires careful planning and specialized care.

Because GT affects the ability of platelets to aggregate normally, pregnancy and childbirth can present significant bleeding challenges. Some women may also develop platelet antibodies that can affect the developing baby.

For these reasons, planning should ideally begin before pregnancy with a hematologist and maternal-fetal medicine specialist familiar with inherited bleeding disorders.

Medical notice: This article is for educational purposes and is not a substitute for individualized medical advice. Pregnancy with Glanzmann Thrombasthenia requires specialist management based on each woman’s medical and bleeding history.

Why Is Pregnancy With Glanzmann Thrombasthenia High Risk?

Glanzmann Thrombasthenia is a rare inherited platelet function disorder involving integrin αIIbβ3, historically called glycoprotein IIb/IIIa.

This receptor helps platelets bind together during platelet aggregation. In GT, αIIbβ3 is absent, reduced, or functions poorly, making it harder for platelets to form an effective platelet plug.

During pregnancy and childbirth, important concerns can include:

• Bleeding during pregnancy or pregnancy complications
• Significant bleeding during or after delivery
• Delayed postpartum hemorrhage
• Complications related to previous platelet transfusions
• Development of antibodies against αIIbβ3
• Low platelet counts and bleeding in the fetus or newborn in certain circumstances

Risk varies by woman with GT. Previous bleeding, transfusions, antibodies, GT subtype, pregnancy history, and other factors can influence management.

Planning for Pregnancy With GT

One of the most important recommendations we can give is to plan before becoming pregnant whenever possible.

Some women with GT use long-term hormonal therapy to control heavy menstrual bleeding. Stopping this treatment to try to conceive can allow significant menstrual bleeding to return.

A preconception evaluation can help identify and address risks before this happens.

Doctors may review:

• Previous serious bleeding episodes
• Heavy menstrual bleeding
• Previous platelet transfusions
• Treatments previously used to control bleeding
• Previous pregnancies or miscarriages
• Previous postpartum hemorrhage
• Anemia and iron deficiency
• Platelet antibodies

Dental and other medical issues may also be better addressed before pregnancy to reduce the need for procedures later.

Genetics and GT Pregnancy

Glanzmann Thrombasthenia is generally inherited in an autosomal recessive pattern and is associated with disease-causing variants involving the ITGA2B or ITGB3 genes.

Knowing a woman’s specific genetic variants can help with genetic counseling before pregnancy. Depending on the circumstances, testing the biological partner may also be appropriate.

For example, if a woman has GT and her partner carries a disease-causing variant in the same relevant gene, the presentation explains that there can be a 50% chance of an affected child.

Genetic counseling can help couples understand their individual risk and reproductive options. Depending on the situation, these may include IVF with preimplantation genetic testing or prenatal diagnostic testing.

These are individual decisions that should be discussed with appropriate genetics, reproductive medicine, hematology, and maternal-fetal medicine specialists.

Why Are Platelet Antibodies Important During Pregnancy?

One of the most important complications of pregnancy with Glanzmann Thrombasthenia is platelet alloimmunization.

Some women with GT develop antibodies against αIIbβ3. Previous platelet transfusions can contribute to antibody development, and pregnancy itself may expose the mother’s immune system to fetal platelet antigens.

These antibodies matter because they can cross the placenta and attack fetal platelets.

This may cause fetal or neonatal thrombocytopenia, meaning the baby’s platelet count becomes abnormally low. In severe cases, this can result in serious bleeding, including intracranial hemorrhage.

The presentation identifies women with Type I GT, where αIIbβ3 expression is very low, as particularly associated with immunization risk.

Testing for relevant platelet antibodies before and during pregnancy can therefore be an important part of specialist care.

Monitoring Pregnancy With Glanzmann Thrombasthenia

Because GT is extremely rare, few high-quality studies establish a single pregnancy-management protocol.

The presentation describes regular monitoring for relevant platelet antibodies during pregnancy. Specialists may also evaluate the fetal brain by ultrasound when fetal bleeding is suspected.

If clinically significant antibodies develop, clinicians may consider treatment to reduce risk to the fetus. The presentation discusses intravenous immunoglobulin (IVIG), sometimes combined with corticosteroids, depending on the woman’s history and risk.

Treatment decisions need to be individualized because the evidence available for GT pregnancy is limited.

Reassuringly, GT itself is not known to increase the overall risk of pregnancy loss, preeclampsia, fetal growth restriction, or stillbirth according to the presentation.

However, complications such as miscarriage or ectopic pregnancy require careful planning because controlling bleeding can be more difficult in someone with GT.

Does Glanzmann Thrombasthenia Require a C-Section?

No. Glanzmann Thrombasthenia alone does not automatically require a cesarean delivery.

The appropriate delivery method should be individualized based on maternal, fetal, and obstetric factors.

A cesarean delivery may be considered when there is a standard obstetric indication or when there are concerns about fetal bleeding, such as significant maternal platelet antibodies, fetal thrombocytopenia, or an affected fetus.

When fetal bleeding is a concern, procedures that could cause trauma to the baby may also need to be avoided.

The presentation reports that no clear relationship has been found between vaginal versus cesarean delivery and the mother’s overall bleeding risk.

Preparing for Labor and Delivery

Delivery should ideally occur at a tertiary-care hospital with an experienced multidisciplinary team.

That team may include hematology, maternal-fetal medicine, obstetrics, anesthesiology, transfusion medicine, genetics, neonatology, laboratory specialists, and pharmacy.

Establish a delivery plan in advance that accounts for both routine delivery and potential emergencies.

The hospital should have rapid access to appropriate blood products and other resources needed to manage major bleeding.

Treatment to prevent or control bleeding is individualized. The presentation discusses approaches involving antifibrinolytic therapy, recombinant activated factor VII (rFVIIa), platelet transfusions, and other measures depending on the patient’s circumstances.

The medical team should determine the exact treatment, timing, and combination rather than following a universal GT protocol.

Postpartum Hemorrhage and Glanzmann Thrombasthenia

Postpartum hemorrhage is one of the most significant concerns for women with GT.

The presentation cites published literature in which postpartum hemorrhage occurred in approximately 40% to 50% of reported pregnancies, including cases where preventive treatment had been used.

Because GT is exceptionally rare and much of the evidence comes from small studies and case reports, do not interpret this percentage as an individual woman’s predicted risk.

Previous postpartum hemorrhage or significant bleeding following miscarriage may indicate greater risk during a future pregnancy.

Importantly, the bleeding risk does not necessarily end after the initial delivery.

Delayed postpartum hemorrhage can occur days or weeks after childbirth. The presentation discusses late postpartum hemorrhage occurring up to six weeks after delivery, with one analysis reporting a median presentation around 10 days.

Women with GT therefore need a postpartum plan explaining what bleeding requires medical attention, whom to contact, and when hematology and obstetric follow-up should occur.

What Happens to the Baby After Delivery?

The newborn may require additional monitoring, particularly when maternal platelet antibodies or genetics create concern.

The presentation recommends checking the baby’s platelet count after delivery and continuing monitoring because the lowest platelet count may not occur immediately at birth.

If thrombocytopenia is identified, specialists may evaluate the newborn for bleeding and determine whether treatment is necessary.

Brain imaging may also be appropriate when significant thrombocytopenia raises concern about intracranial bleeding.

Glanzmann Thrombasthenia itself does not generally prevent breastfeeding, although additional considerations may apply when the newborn has thrombocytopenia.

Frequently Asked Questions About GT and Pregnancy

Pregnancy With GT Requires Individualized Planning

Pregnancy with Glanzmann Thrombasthenia is possible, but there is no single management plan appropriate for every woman with GT.

Previous bleeding, genetics, GT subtype, platelet antibodies, transfusion history, pregnancy history, and fetal risk can all influence care.

The most important step for a woman with Glanzmann Thrombasthenia who is considering pregnancy is to begin planning before conception whenever possible.

Working with a hematologist and maternal-fetal medicine specialist who understand inherited bleeding disorders allows risks to be identified early. It creates a plan for pregnancy, delivery, and the postpartum period that reflects the individual woman rather than assumptions about GT.